A Phase 2 proof-of-concept trial evaluating the efficacy of XEN901 as a treatment for adult focal seizures or for rare, pediatric forms of epilepsy
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2018
At a glance
- Drugs XEN 901 (Primary)
- Indications Epilepsy; Seizures
- Focus Proof of concept; Therapeutic Use
- Sponsors Xenon Pharmaceuticals
- 29 Aug 2018 According to a Xenon Pharmaceuticals media release, upon completion of a phase 1 trial of XEN901 and read-out of its final results (CT profile 282613), the company expects to initiate this trial as soon as feasible thereafter depending on planned discussions with regulatory agencies in the near term.
- 11 Jan 2018 New trial record
- 08 Jan 2018 According to a Xenon Pharmaceuticals media release, this trial is expected to begin by year-end 2018.